Skip to main content

Human Papilloma Virus

9
Pipeline Programs
10
Companies
13
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
375%
Vaccine
125%
+ 20 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
7 programs
3
1
quadrivalent human papillomavirusPhase 3
Gardasil9Phase 1
LenvatinibPhase 1Small Molecule
Octavalent HPV with 15 mcg IMX / AAHSPhase 1
Acceptance of Human Papillomavirus Vaccination in Postpartum WomenN/A
+2 more programs
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
7 programs
3
1
quadrivalent human papillomavirusPhase 31 trial
Gardasil9Phase 11 trial
LenvatinibPhase 1Small Molecule1 trial
Octavalent HPV with 15 mcg IMX / AAHSPhase 11 trial
Acceptance of Human Papillomavirus Vaccination in Postpartum WomenN/A1 trial
+2 more programs
Active Trials
NCT00730704Completed150Est. Oct 2012
NCT06229353Terminated34Est. Jul 2025
NCT06255938Unknown200Est. Feb 2026
+4 more trials
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
2 programs
1
Mobile ClinicPhase 11 trial
Health Messaging via SMSN/A1 trial
Active Trials
NCT03759236Completed3Est. Feb 2020
NCT03953911Unknown3Est. Jun 2020
Merck & Co.
Merck & Co.RAHWAY, NJ
3 programs
Acceptance of Human Papillomavirus Vaccination in Postpartum WomenN/A
smearsN/A
quadrivalent human papillomavirusPHASE_3
Alliance Pharmaceuticals
1 program
AFIX OnlyN/A1 trial
Active Trials
NCT03824093Completed225Est. May 2020
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Comprehensive Vaccine Promotion PackageN/AVaccine1 trial
Active Trials
NCT03186430Completed168Est. Jul 2018
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
Practice facilitationN/A1 trial
Active Trials
NCT03604393Unknown22,000Est. Jun 2023
Atila Biosystems
Atila BiosystemsCA - Sunnyvale
1 program
Prevention of Cervical Cancer Using the Genotyping Screening and Same-day Self-samplingN/A1 trial
Active Trials
NCT07232355Recruiting5,000Est. Jun 2026
Eisai
EisaiChina - Liaoning
1 program
LenvatinibPHASE_1Small Molecule

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Sharp Therapeuticsquadrivalent human papillomavirus
Sharp TherapeuticsLenvatinib
Sharp TherapeuticsGardasil9
Angeles TherapeuticsMobile Clinic
Sharp TherapeuticsOctavalent HPV with 15 mcg IMX / AAHS
Sharp TherapeuticsGardasil 9
Sharp Therapeuticssmears
Atila BiosystemsPrevention of Cervical Cancer Using the Genotyping Screening and Same-day Self-sampling
Oregon TherapeuticsPractice facilitation
Alliance PharmaceuticalsAFIX Only
Angeles TherapeuticsHealth Messaging via SMS
Allergy TherapeuticsComprehensive Vaccine Promotion Package
Sharp TherapeuticsAcceptance of Human Papillomavirus Vaccination in Postpartum Women

Clinical Trials (13)

Total enrollment: 28,616 patients across 13 trials

NCT02382900Sharp Therapeuticsquadrivalent human papillomavirus

Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City

Start: Feb 2015Est. completion: Dec 2015500 patients
Phase 3Unknown
NCT04645602Sharp TherapeuticsLenvatinib

Merck IIT: RRP Pembro and Lenvatinib

Start: Jul 2025Est. completion: Dec 202720 patients
Phase 1Recruiting
NCT05329961Sharp TherapeuticsGardasil9

Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old

Start: Sep 2022Est. completion: Dec 2028155 patients
Phase 1Active Not Recruiting
NCT03953911Angeles TherapeuticsMobile Clinic

Increasing HPV Vaccination Rates Via Educational Interventions in Schools Located Within Cedars-Sinai Catchment Areas

Start: May 2019Est. completion: Jun 20203 patients
Phase 1Unknown
NCT00851643Sharp TherapeuticsOctavalent HPV with 15 mcg IMX / AAHS

Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)

Start: Apr 2006Est. completion: Nov 2009158 patients
Phase 1Completed
NCT06229353Sharp TherapeuticsGardasil 9

Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department

Start: Aug 2024Est. completion: Jul 202534 patients
N/ATerminated
NCT06255938Sharp Therapeuticssmears

Prevalence of HPV (Human Papilloma Virus) and HPV Vaccination Among Victims of Sexual Violence

Start: Feb 2024Est. completion: Feb 2026200 patients
N/AUnknown
NCT07232355Atila BiosystemsPrevention of Cervical Cancer Using the Genotyping Screening and Same-day Self-sampling

Prevention of Cervical Cancer Using the Genotyping Screening and Same-day Self-sampling

Start: Aug 2023Est. completion: Jun 20265,000 patients
N/ARecruiting
NCT03604393Oregon TherapeuticsPractice facilitation

Increasing HPV Immunization Rates: The Rural Adolescent Vaccine Enterprise

Start: Jun 2019Est. completion: Jun 202322,000 patients
N/AUnknown
NCT03824093Alliance PharmaceuticalsAFIX Only

High and Low Resource Interventions to Promote HPV Vaccines

Start: Jul 2018Est. completion: May 2020225 patients
N/ACompleted
NCT03759236Angeles TherapeuticsHealth Messaging via SMS

Increasing Human Papillomavirus (HPV) Vaccine Uptake Via General Health Messaging

Start: Apr 2018Est. completion: Feb 20203 patients
N/ACompleted
NCT03186430Allergy TherapeuticsComprehensive Vaccine Promotion Package

PreTeenVax Evaluation

Start: Jun 2017Est. completion: Jul 2018168 patients
N/ACompleted
NCT00730704Sharp TherapeuticsAcceptance of Human Papillomavirus Vaccination in Postpartum Women

Acceptance of Human Papillomavirus Vaccination in Postpartum Women

Start: May 2009Est. completion: Oct 2012150 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 28,616 patients
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.